Our findings align with previous meta-analytical evidence [27] and further confirm in a real-world setting (where comorbidities and variable adherence may influence therapeutic outcomes) the long-term efficacy of anti-IL-5 therapy, thus highlighting the beneficial impact on asthma control and its modulatory effects on immunometabolic profiles. The gene discussed is IL5; the disease is asthma.